Ignite Creation Date:
2025-12-24 @ 5:20 PM
Ignite Modification Date:
2026-01-13 @ 9:20 PM
Study NCT ID:
NCT03349450
Status:
COMPLETED
Last Update Posted:
2023-11-02
First Post:
2017-11-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
DPX-Survivac and Checkpoint Inhibitor in DLBCL
Sponsor:
Sunnybrook Health Sciences Centre
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | DLBCL | View |
| None | Lymphoma, B-Cell | View |
| None | Lymphoma, Large B-Cell, Diffuse | View |
| None | Neoplasms by Histologic Type | View |
| None | Neoplasms | View |
| None | Lymphoproliferative Disorders | View |
| None | Lymphatic Diseases | View |
| None | Immunoproliferative Disorders | View |
| None | Immune System Diseases | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | Cyclophosphamide | View |
| None | Pembrolizumab | View |
| None | Immunosuppressive Agents | View |
| None | Immunologic Factors | View |
| None | Physiological Effects of Drugs | View |
| None | Antirheumatic Agents | View |
| None | Antineoplastic Agents, Alkylating | View |
| None | Alkylating Agents | View |
| None | Molecular Mechanisms of Pharmacological Action | View |
| None | Antineoplastic Agents | View |
| None | Myeloablative Agonists | View |
| None | Canada | View |
| None | Ontario | View |
| None | Diffuse Large B Cell Lymphoma | View |
| None | refractory | View |
| None | relapsed | View |
| None | checkpoint inhibitor | View |
| None | vaccine | View |
| None | DPX-Survivac | View |
| None | Survivin | View |
| None | Immunotherapy | View |
| None | Transformed Lymphoma | View |
| None | Double Hit | View |
| None | Large Cell Lymphoma | View |
| None | Keytruda | View |